Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.
16hon MSN
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results